<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>News</title>
	<atom:link href="https://www.worldpharmatoday.com/news/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Wed, 18 Nov 2026 13:34:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>News</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Körber Launches PAS-X Neo MES for Small Pharma Manufacturers</title>
		<link>https://www.worldpharmatoday.com/news/korber-launches-pas-x-neo-mes-for-small-pharma-manufacturers/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 13:34:12 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/korber-launches-pas-x-neo-mes-for-small-pharma-manufacturers/</guid>

					<description><![CDATA[<p>Technology company Körber has introduced a new manufacturing execution system tailored specifically for smaller pharmaceutical sites, where the complexity and cost of a full-scale MES implementation have historically made it difficult to move away from paper-based processes. The new solution, called PAS-X Neo, is designed with small and medium-sized manufacturers in mind, as well as [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/korber-launches-pas-x-neo-mes-for-small-pharma-manufacturers/">Körber Launches PAS-X Neo MES for Small Pharma Manufacturers</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>How Bullying Affects Young People’s Mental Health</title>
		<link>https://www.worldpharmatoday.com/news/how-bullying-affects-young-peoples-mental-health/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 10:19:06 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/how-bullying-affects-young-peoples-mental-health/</guid>

					<description><![CDATA[<p>Bullying is sometimes brushed off as a normal part of growing up. Many adults remember teasing or name-calling from their own school years and assume kids will simply get through it. But research and the experiences of countless families show that bullying can have real and lasting effects on a young person’s emotional well-being. Understanding [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/how-bullying-affects-young-peoples-mental-health/">How Bullying Affects Young People’s Mental Health</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Supplement Distribution Is a cGMP Problem, Not Just a Logistics One</title>
		<link>https://www.worldpharmatoday.com/news/supplement-distribution-is-a-cgmp-problem-not-just-a-logistics-one/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 18 Nov 2026 09:20:54 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/supplement-distribution-is-a-cgmp-problem-not-just-a-logistics-one/</guid>

					<description><![CDATA[<p>Three in four U.S. adults take dietary supplements, according to the Council for Responsible Nutrition’s 2026 consumer survey. Most of the quality conversation around those products still stops at the production line: ingredient sourcing, potency testing, batch release. Then the finished goods move to a warehouse, and the paperwork thins out. That’s a mistake. Once [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/supplement-distribution-is-a-cgmp-problem-not-just-a-logistics-one/">Supplement Distribution Is a cGMP Problem, Not Just a Logistics One</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping</title>
		<link>https://www.worldpharmatoday.com/news/insulated-pallet-protection-in-temperature-sensitive-pharmaceutical-shipping/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 14 Nov 2026 07:11:16 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/insulated-pallet-protection-in-temperature-sensitive-pharmaceutical-shipping/</guid>

					<description><![CDATA[<p>In the pharmaceutical industry, products frequently require very specific temperatures to maintain quality and/or specific functions. Shipments are prone to risks as a result of inclement weather, loading time delays, and long transfers. So, it is important to plan and protect them. The effect of temperature changes outside the container is decreased by effectively providing [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/insulated-pallet-protection-in-temperature-sensitive-pharmaceutical-shipping/">Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Litmys and PharmaACE Establish Strategic Partnership for Market Projections</title>
		<link>https://www.worldpharmatoday.com/news/litmys-and-pharmaace-establish-strategic-partnership-for-market-projections/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 12:57:56 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[IT & Data Management]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/litmys-and-pharmaace-establish-strategic-partnership-for-market-projections/</guid>

					<description><![CDATA[<p>Life sciences consulting firms Litmys and PharmaACE have officially announced a strategic collaboration designed to deliver specialised decision-making and commercial forecasting solutions to the biotechnology and pharmaceutical sectors. This newly formed partnership specifically integrates real-world product adoption analytics with sophisticated commercial modelling. The core objective is to support companies in making informed choices regarding clinical [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/litmys-and-pharmaace-establish-strategic-partnership-for-market-projections/">Litmys and PharmaACE Establish Strategic Partnership for Market Projections</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Blackstone Provides Up to $1.5 Billion for Pfizer&#8217;s Obesity Drug Candidate</title>
		<link>https://www.worldpharmatoday.com/news/blackstone-provides-up-to-1-5-billion-for-pfizers-obesity-drug-candidate/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 12:51:59 +0000</pubDate>
				<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pfizer]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/blackstone-provides-up-to-1-5-billion-for-pfizers-obesity-drug-candidate/</guid>

					<description><![CDATA[<p>Private equity firm Blackstone Life Sciences has agreed to supply Pfizer with up to $1.5 billion in funding for the latter’s once-monthly candidate berobenatide. This capital infusion will directly support the ambitious GLP-1 drug development strategy for berobenatide, which is intended to offer patients less frequent injections compared to the current generation of once-weekly therapies [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/blackstone-provides-up-to-1-5-billion-for-pfizers-obesity-drug-candidate/">Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment</title>
		<link>https://www.worldpharmatoday.com/news/how-biopharmaceutical-research-is-shaping-the-future-of-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 12 Nov 2026 10:52:48 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/how-biopharmaceutical-research-is-shaping-the-future-of-cancer-treatment/</guid>

					<description><![CDATA[<p>Cancer is no longer viewed solely as a clinical condition to be treated using standard methods of cancer therapy. Ongoing research into cancer biology and its diverse molecular characteristics is supporting the investigation of emerging therapeutic strategies and clinical trials of investigational cancer treatments. These approaches are increasingly designed to target specific molecular changes and [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/how-biopharmaceutical-research-is-shaping-the-future-of-cancer-treatment/">How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>What Pharmaceutical Professionals Should Know About AI Scribes</title>
		<link>https://www.worldpharmatoday.com/news/what-pharmaceutical-professionals-should-know-about-ai-scribes/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 10 Nov 2026 13:21:56 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/what-pharmaceutical-professionals-should-know-about-ai-scribes/</guid>

					<description><![CDATA[<p>A clinic pharmacist ends the day with twenty unsigned notes, and software she never checked wrote the first drafts. That scene is now common as ambient tools spread through clinics, pharmacies, and research sites. Federal privacy rules are tightening too. A proposed HIPAA Security Rule update raises the bar for how electronic patient data is [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/what-pharmaceutical-professionals-should-know-about-ai-scribes/">What Pharmaceutical Professionals Should Know About AI Scribes</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>7 Questions to Consider Before Choosing an AI Scribe for Your Practice</title>
		<link>https://www.worldpharmatoday.com/news/7-questions-to-consider-before-choosing-an-ai-scribe-for-your-practice/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 06 Nov 2026 13:42:33 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/7-questions-to-consider-before-choosing-an-ai-scribe-for-your-practice/</guid>

					<description><![CDATA[<p>Clinic days move quickly, and documentation often becomes the work that follows clinicians home. When notes, inbox messages, refill requests, coding checks, and patient follow-ups all compete for attention, an AI scribe can look like an obvious solution. Yet choosing one based on a polished demonstration alone can create another workflow problem instead of solving [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/7-questions-to-consider-before-choosing-an-ai-scribe-for-your-practice/">7 Questions to Consider Before Choosing an AI Scribe for Your Practice</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Best GxP Validation Software for Pharma in 2026: 7 Platforms Ranked</title>
		<link>https://www.worldpharmatoday.com/news/best-gxp-validation-software-for-pharma-in-2026-7-platforms-ranked/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 04 Nov 2026 13:19:46 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/best-gxp-validation-software-for-pharma-in-2026-7-platforms-ranked/</guid>

					<description><![CDATA[<p>Short answer: the best GxP validation software in 2026 is Matrix Validate, followed by ValGenesis, Kneat Gx, Veeva Validation Management, Valkit.ai, Res_Q by Sware and Validfor. Matrix Validate is first because it is built for the pharma CSV team: requirements, risks and tests are connected data, risk sets test depth in line with GAMP 5 [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/best-gxp-validation-software-for-pharma-in-2026-7-platforms-ranked/">Best GxP Validation Software for Pharma in 2026: 7 Platforms Ranked</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
